Objective Tekton’s Wichita, KS site with lead PI Dr. Brandon Alleman was selected to support a recent clinical trial evaluating a continuous glucose monitoring (CGM) device in pregnant women with diabetes. Pregnancy introduces unique challenges in managing glucose levels, making CGM a vital tool for optimizing maternal and fetal health. Challenge The study presented unique … Read more
Overview Tekton Research delivered exceptional results in a recent Type 1 Diabetes clinical trial by leveraging its multi-site endocrinology expertise, operational efficiency, and proven site management processes. All three Tekton sites exceeded enrollment targets, contributing to the study’s success. Key Metrics 172% Average enrollment across 3 sitesGoal: 18 | Enrolled: >30 1 days Average regulatory … Read more
Overview Tekton Research played a pivotal role in advancing a recent Alzheimer’s Disease clinical trial, demonstrating exceptional performance across enrollment, site readiness, and strategic consultation. Our team not only enrolled the study’s first patient but also exceeded initial recruitment expectations, delivering high-quality data while supporting a newly engaged Principal Investigator (PI) through our robust training … Read more
Objective Tekton was selected to deliver research sites and participants for a Global Phase 3 vaccine clinical trial. The study required a population of generally healthy adults and demanded rapid site activation and participant enrollment to meet aggressive study timelines. Challenge Norovirus, a highly contagious virus causing gastrointestinal illness, presents significant global public health challenges. … Read more
Objective Tekton was selected to deliver research sites and participants for a Global Phase 3 vaccine clinical trial. The trial required a patient population of generally healthy adults aged ≥50, stratified into three age groups. Challenge Vaccine season brings a surge of clinical research activity—especially for flu-related studies. At the time of this trial, several … Read more